Moneycontrol
HomeNewsBusinessRBI in battle-ready mode, says Shaktikanta Das on liquidity needs of NBFCs
Trending Topics

RBI in battle-ready mode, says Shaktikanta Das on liquidity needs of NBFCs

Bank boards must clear the policy on offering moratorium on loans; RBI has approved it and the onus now remains on the banks, RBI Governor Shaktikanta Das told Cogencis in an interview. Read on for the key highlights

April 27, 2020 / 14:08 IST
Story continues below Advertisement
Reserve Bank of India (RBI) Governor Shaktikanta Das

Following are the highlights of Reserve Bank of India Governor Shaktikanta Das' first interview since the beginning of the nationwide lockdown announced over a month ago.

In an hour-long interview to Cogencis, Das said even though there is an animated discussion on the subject of the central bank monetising the government's budget deficit amidst the ongoing fight against COVID-19 pandemic, he has not taken a view on the issue yet.

Story continues below Advertisement

Key highlights:

*Fiscal measures key to combat economic impact of COVID-19
*FY21 fiscal gap going beyond 3.5 percent becomes unavoidable
*RBI has not taken a view on the monetisation of government deficit
*On the issue of monetisation, RBI must keep operational realities in sight, preserve RBI's balance sheet strength
*Will evaluate alternative funding sources for fiscal deficit
*Won't make specific comment on the private placement of bonds with RBI
*Will take a judicious, balanced call if RBI will take bond private placements
*Not taken any view on COVID bonds
*Repo rate, as decided by MPC, is the "single" policy rate; alone conveys the stance of monetary policy

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show